New insider activity at Aura Biosciences Inc ( (AURA) ) has taken place on October 16, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CTO Mark Plavsic recently made headlines by selling 12,169 shares of Aura Biosciences Inc, a transaction valued at $77,273. This move has caught the attention of investors and market watchers, eager to understand the implications of this significant sale.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
Aura Biosciences’ overall stock score reflects its early-stage biotech profile, characterized by no revenue, increasing losses, and negative cash flows. While the company maintains a solid balance sheet, its stock faces bearish technical indicators and speculative valuation. The recent board appointment is a positive development, but the company’s financial health and market trends remain the primary concerns.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
YTD Price Performance: -23.12%
Average Trading Volume: 214,095
Technical Sentiment Signal: Sell
Current Market Cap: $394.5M